Ensign Peak Advisors Inc increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,669,871 shares of the biopharmaceutical company's stock after purchasing an additional 60,474 shares during the quarter. Ensign Peak Advisors Inc owned 0.13% of Gilead Sciences worth $154,246,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Principal Financial Group Inc. boosted its holdings in shares of Gilead Sciences by 4.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,451,249 shares of the biopharmaceutical company's stock valued at $121,673,000 after buying an additional 59,181 shares in the last quarter. ORG Partners LLC boosted its holdings in shares of Gilead Sciences by 0.3% during the 4th quarter. ORG Partners LLC now owns 66,317 shares of the biopharmaceutical company's stock valued at $6,126,000 after buying an additional 225 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Gilead Sciences by 0.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 324,469 shares of the biopharmaceutical company's stock valued at $29,971,000 after buying an additional 1,458 shares in the last quarter. ORG Wealth Partners LLC boosted its holdings in shares of Gilead Sciences by 83.0% during the 4th quarter. ORG Wealth Partners LLC now owns 2,401 shares of the biopharmaceutical company's stock valued at $222,000 after buying an additional 1,089 shares in the last quarter. Finally, Harbor Capital Advisors Inc. boosted its holdings in shares of Gilead Sciences by 2.3% during the 4th quarter. Harbor Capital Advisors Inc. now owns 27,621 shares of the biopharmaceutical company's stock valued at $2,551,000 after buying an additional 616 shares in the last quarter. 83.67% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on the company. Oppenheimer reduced their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. BMO Capital Markets upped their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Bank of America upped their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $110.55.
Read Our Latest Research Report on GILD
Gilead Sciences Trading Down 1.3%
Shares of GILD traded down $1.30 during midday trading on Friday, reaching $96.86. The company had a trading volume of 13,140,489 shares, compared to its average volume of 7,595,228. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The stock has a market cap of $120.61 billion, a PE ratio of 261.78, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The firm has a 50 day simple moving average of $107.23 and a 200-day simple moving average of $99.39. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same period in the prior year, the firm posted ($1.32) earnings per share. The firm's quarterly revenue was down .3% on a year-over-year basis. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 3.26%. Gilead Sciences's dividend payout ratio is presently 66.53%.
Insider Buying and Selling
In other news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the transaction, the chief financial officer now owns 169,061 shares in the company, valued at approximately $19,977,938.37. This trade represents a 9.59% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 160,605 shares of company stock valued at $16,718,136. Corporate insiders own 0.27% of the company's stock.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
